BioGend Therapeutics Co., Ltd. (TPEX:6733)
Taiwan · Delayed Price · Currency is TWD 44.30
+0.35 (0.80%)
Oct 31, 2025, 1:30 PM CST
BioGend Therapeutics Market Cap
BioGend Therapeutics has a market cap or net worth of 5.5 billion as of October 31, 2025. Its market cap has increased by 16.58% in one year.
Market Cap
5.50B
Enterprise Value
4.96B
Revenue
195.02M
Ranking
n/a
PE Ratio
n/a
Stock Price
44.30
Market Cap Chart
Since June 18, 2019, BioGend Therapeutics's market cap has increased from 2.71B to 5.50B, an increase of 102.81%. That is a compound annual growth rate of 11.73%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Oct 31, 2025 | 5.50B | 31.65% |
| Dec 31, 2024 | 4.18B | -11.18% |
| Dec 29, 2023 | 4.71B | 109.50% |
| Dec 30, 2022 | 2.25B | -18.50% |
| Dec 30, 2021 | 2.76B | -22.86% |
| Dec 31, 2020 | 3.57B | 46.27% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 18, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Caliway Biopharmaceuticals | 233.43B |
| PharmaEssentia | 184.18B |
| Lotus Pharmaceutical | 77.71B |
| Bora Pharmaceuticals Co., LTD. | 77.08B |
| Lumosa Therapeutics | 35.38B |
| Oneness Biotech | 30.99B |
| Pegavision | 26.56B |
| Polaris Group | 26.43B |